Notice of Closed Meeting, 5441 [2020-01622]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 20 / Thursday, January 30, 2020 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
people. We will be broadcasting the
meeting live via Webcast at https://
www.cms.gov/live/.
DATES: The meeting will be held on
March 17, 2020, 9:00 a.m. to 5:00 p.m.,
EDT and March 18,2020, 9:00 a.m. to
5:00 p.m., EDT.
ADDRESSES: Centers for Medicare and
Medicaid Services (CMS) Auditorium,
7500 Security Boulevard, Baltimore,
Maryland 21244.
FOR FURTHER INFORMATION CONTACT:
Traci Ramirez, Program Specialist, CDC,
3311 Toledo Road, Hyattsville,
Maryland 20782; telephone: (301) 458–
4454; TRamirez@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The ICD–10 Coordination
and Maintenance (C&M) Committee is a
public forum for the presentation of
proposed modifications to the
International Classification of Diseases,
Tenth Revision, Clinical Modification
and ICD–10 Procedure Coding System.
Matters to be Considered: The
tentative agenda will include
discussions on ICD–10–CM and ICD–
10–PCS topics listed below. Agenda
items are subject to change as priorities
dictate.
Please refer to the posted agenda for
updates one month prior to the meeting.
ICD–10–PCS Topics
Microbial Testing
Insertion of Subcutaneous Pump System
for Ascites Drainage
Insertion of Carotid Baroceptor
Stimulator Pulse Generator
Infectious Disease Testing
Administration of BREYANZI®
(lisocabtagene maraleucel)
Administration of FETROJA®
(cefiderocol)
CT Angiogram with Computer-Aided
Triage and Notification
Endoscopic Gastrointestinal Hemostat
Administration of IMFINZI®
(durvalumab)
Intramedullary Joint Fusion System
Peripheral Intravascular Lithotripsy
(IVL)
Administration of KTE–X19
Administration of NUZYRA®
(omadacycline)
Administration of OTL–101
Administration of Sivextro (tedizolid
phosphate)
Administration of Soliris® (eculizumab)
Transcarotid Arterial Revascularization
with Embolic
Neuroprotection
Implantable Fracture Reduction System
Administration of TECENTRIQ®
(atezolizumab)
Administration of TERLIVAZ®
(terlipressin)
Administration of XENLETA®
(lefamulin)
VerDate Sep<11>2014
16:56 Jan 29, 2020
Jkt 250001
Administration of ZERBAXA®
(ceftolozane and tazobactam)
Addenda
ICD–10–CM Topics
Anaplasmosis
Breast implant illness
Cough
Electronic nicotine delivery devices
Endometriosis
Non-ischemic heart disease
Non-radiographic axial
spondyloarthritis
Synthetic cannabinoids
Addenda
Security Considerations: Due to
increased security requirements, CMS
has instituted stringent procedures for
entrance into the building by nongovernment employees. Attendees will
need to present valid government-issued
picture identification, and sign-in at the
security desk upon entering the
building.
Attendees who wish to attend the
March 17–18, 2020, ICD–10–CM C&M
meeting must submit their name and
organization by March 6, 2020, for
inclusion on the visitor list. This visitor
list will be maintained at the front desk
of the CMS building and used by
security to admit visitors to the meeting.
To request reasonable accommodation,
please contact the CMS Reasonable
Accommodation Program at Email
reasonableaccommodationprogram@
cms.hhs.gov.
Participants who attended previous
Coordination and Maintenance meetings
will no longer be automatically added to
the visitor list. You must request
inclusion of your name prior to each
meeting you wish attend.
Please register to attend the meeting
on-line at: https://www.cms.hhs.gov/
apps/events/.
Please contact Mady Hue (410–786–
4510) or Marilu.hue@cms.hhs.gov for
questions about the registration process.
Note: CMS and NCHS no longer
provide paper copies of handouts for the
meeting. Electronic copies of all meeting
materials will be posted on the CMS and
NCHS websites prior to the meeting at
https://www.cms.hhs.gov/ICD9Provider
DiagnosticCodes/03_
meetings.asp#TopOfPage and https://
www.cdc.gov/nchs/icd/icd10cm_
maintenance.htm.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
5441
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–01756 Filed 1–29–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease, Disability,
and Injury Prevention and Control Special
Emphasis Panel (SEP)—SIP20–003,
Improving Genetic Counseling Referrals for
Early Onset Colorectal Cancer.
Date: April 24, 2020.
Time: 11:00 a.m.–6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant
applications.
For Further Information Contact: Jaya
Raman Ph.D., Scientific Review Officer, CDC,
4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341; Telephone: (770) 488–6511;
kva5@cdc.gov.
The Director, Strategic Business Initiatives
Unit, Office of the Chief Operating Officer,
Centers for Disease Control and Prevention,
has been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for both
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2020–01622 Filed 1–29–20; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\30JAN1.SGM
30JAN1
]]>Agencies
[Federal Register Volume 85, Number 20 (Thursday, January 30, 2020)]
[Notices]
[Page 5441]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-01622]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention
and Control Special Emphasis Panel (SEP)--SIP20-003, Improving
Genetic Counseling Referrals for Early Onset Colorectal Cancer.
Date: April 24, 2020.
Time: 11:00 a.m.-6:00 p.m., EDT.
Place: Teleconference.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Jaya Raman Ph.D., Scientific
Review Officer, CDC, 4770 Buford Highway, Mailstop F80, Atlanta,
Georgia 30341; Telephone: (770) 488-6511; [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-01622 Filed 1-29-20; 8:45 am]
BILLING CODE 4163-18-P
